---
title: "Aardvark Therapeutics Unveils Positive Obesity Drug Data at ObesityWeek 2025"
description: "Aardvark Therapeutics Inc. will present new data on its obesity drug pipeline at ObesityWeek 2025 in Atlanta from November 4-7, 2025. The company will showcase investigational compounds ARD-101 and WE"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262236459.md"
published_at: "2025-10-22T12:00:28.000Z"
---

# Aardvark Therapeutics Unveils Positive Obesity Drug Data at ObesityWeek 2025

> Aardvark Therapeutics Inc. will present new data on its obesity drug pipeline at ObesityWeek 2025 in Atlanta from November 4-7, 2025. The company will showcase investigational compounds ARD-101 and WE-868, with presentations by CSO Timothy Kieffer and CEO Tien Lee on November 4. An investor webinar is scheduled for November 5 to discuss the data and updates on ARD-101’s development in Prader-Willi Syndrome, with an archived recording available for a month post-event.

Aardvark Therapeutics Inc. announced that it will present new data from its pipeline programs at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. The company will share poster presentations on its investigational compounds, including ARD-101, a TAS2R pan-agonist evaluated for its effects on weight gain in mice and hunger reduction in adults with obesity, and WE-868, an isoflavonoid modulator of oxidative metabolism with therapeutic potential in obesity and diabetes. The data will be presented by Chief Scientific Officer Timothy Kieffer, Ph.D., and Chief Executive Officer Tien Lee, M.D., on November 4, 2025. Additionally, Aardvark will host an investor webinar on November 5, 2025, to discuss the presented data and provide updates on ARD-101’s development in Prader-Willi Syndrome. The company will make an archived recording of the webinar available on its website for approximately one month after the event. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549733-en) on October 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [AARD.US - Aardvark Therapeutics](https://longbridge.com/en/quote/AARD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Aardvark Therapeutics Receives IRB Approval for Expanded Phase 3 HERO Trial Eligibility | Aardvark Therapeutics Inc. has received IRB approval for an amended protocol in its Phase 3 HERO trial, which evaluates  | [Link](https://longbridge.com/en/news/275461906.md) |
| Buy Rating for Aardvark Therapeutics: ARD-101’s Potential in Prader-Willi Syndrome Treatment | James Condulis has issued a Buy rating for Aardvark Therapeutics, Inc.’s ARD-101, highlighting its potential in treating | [Link](https://longbridge.com/en/news/259285514.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/en/news/276017486.md) |
| 13:12 ETQuestar Solutions Announces Major Expansion with New Corporate Headquarters and Atlanta Distribution Center | Questar Solutions has announced a major expansion, relocating its corporate headquarters and North Canton warehouse to a | [Link](https://longbridge.com/en/news/275498183.md) |
| 08:07 ETATN Demonstration Pilot Breaks Ground at SMDO26, Marking a Major Milestone for Innovative Transit in South Metro Atlanta | The ATL Airport Community Improvement Districts (AACIDs) has broken ground on its Automated Transit Network (ATN) Demons | [Link](https://longbridge.com/en/news/275610080.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.